Quarterly results round-up: Beckman still strong overall, as Gen-Probe misses expectations
This article was originally published in Clinica
Beckman Coulter reported third-quarter revenue of $893.8m, which was up by around 9% compared to the same period last year. The growth was attributed, in part, to the acquired Olympus lab-based diagnostics division. The acquisition helped to considerably bulk up Beckman's chemistry and clinical automation business, which recorded 14% reported growth in sales, at $323.2m. This, in turn, helped to drive, clinical diagnostics revenue, which reached $787.6m (11% reported growth). Geographically, strong sales in Asia-Pacific and emerging markets helped to off-set softness in developed markets. Beckman’s net income for the period was $67m, a significant improvement on Q3 2009 which was impacted by $79.2m in restructuring charges and reported earnings of $1.5m.